Back to Journals » Neuropsychiatric Disease and Treatment » Volume 2 » Issue 4

Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder

Authors Feng Liu, Haruka Minami, Raul R Silva

Published 15 December 2006 Volume 2006:2(4) Pages 467—473

Feng Liu, Haruka Minami, Raul R Silva

New York University School of Medicine, Division of Child and Adolescent Psychiatry, New York, NY, USA

Abstract: Attention-deficit/hyperactivity disorder (ADHD) affects a large number of children. For decades, the stimulants have been the mainstay of pharmacological treatment for ADHD. Dexmethylphenidate (d-MPH), the d-isomer of the traditional racemic mixtures of d,l-threo-(R,R)-MPH, was recently introduced as another potential option in the stimulant class of medications. This paper reviews and summarizes the available research literature on d-MPH regarding pharmacodynamic, pharmacokinetic, chemical structure, receptor binding, toxicology, and clinical perspectives. d-MPH potentially may offer some advantages in the realms of absorption and duration of action compared with its racemic counterpart. The differences in pharmacokinetics and clinical implications of the immediate-release and extended-release forms of d-MPH are also compared and contrasted.

Keywords: ADHD, dexmethylphenidate, chemistry, receptor binding, toxicology, pharmacokinetics

Download Article [PDF] 

Readers of this article also read:

Covalent IR820-PEG-diamine nanoconjugates for theranostic applications in cancer

Fernandez-Fernandez A, Manchanda R, Carvajal DA, Lei T, Srinivasan S, McGoron AJ

International Journal of Nanomedicine 2014, 9:4631-4648

Published Date: 6 October 2014

Surface engineered antifouling optomagnetic SPIONs for bimodal targeted imaging of pancreatic cancer cells

Wang X, Xing X, Zhang B, Liu F, Cheng Y, Shi D

International Journal of Nanomedicine 2014, 9:1601-1615

Published Date: 27 March 2014

Survival of women with breast cancer in central and northern Denmark, 1998–2009

Lietzen LW, Sørensen GV, Ording AG, Garne JP, Christiansen P, Nørgaard M, Jacobsen J

Clinical Epidemiology 2011, 3:35-40

Published Date: 21 July 2011

Release profile and stability evaluation of optimized chitosan/alginate nanoparticles as EGFR antisense vector

Ebrahim Azizi, Alireza Namazi, Ismaeil Haririan, et al

International Journal of Nanomedicine 2010, 5:455-461

Published Date: 29 June 2010

Valuing the person’s story: Use of life story books in a continuing care setting

Teresa Wills, Mary Rose Day

Clinical Interventions in Aging 2008, 3:547-552

Published Date: 12 September 2008

Predictors of social cognition in patients with schizophrenia

Daniela Mirabilio, Silvia Di Tommaso, Ilaria Riccardi, Massimo Marinelli, Enrico Daneluzzo, Paolo Stratta, Luigi D’Albenzio, Alessandro Rossi

Neuropsychiatric Disease and Treatment 2006, 2:571-576

Published Date: 15 December 2006

Schizophrenia-like psychosis and aceruloplasminemia

Mark Walterfang, Evrim March, Daniel Varghese, Kathryn Miller, Leonie Simpson, Bruce Tomlinson, Dennis Velakoulis

Neuropsychiatric Disease and Treatment 2006, 2:577-581

Published Date: 15 December 2006

Rizatriptan in the treatment of migraine

Miguel JA Láinez

Neuropsychiatric Disease and Treatment 2006, 2:247-259

Published Date: 15 September 2006

Topiramate in the prevention of migraine: a review of its efficacy, tolerability, and acceptability

Domenico D’Amico, Licia Grazzi, Gennaro Bussone

Neuropsychiatric Disease and Treatment 2006, 2:261-267

Published Date: 15 September 2006

Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial

Frederick W Reimherr, Dawson W Hedges, Robert E Strong, Barrie K Marchant, Erika D Williams

Neuropsychiatric Disease and Treatment 2005, 1:245-251

Published Date: 15 October 2005